| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ... Jama 311 (19), 1998-2006, 2014 | 1912 | 2014 |
| Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability R Sears, F Nuckolls, E Haura, Y Taya, K Tamai, JR Nevins Genes & development 14 (19), 2501-2514, 2000 | 1632 | 2000 |
| Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis G Niu, KL Wright, M Huang, L Song, E Haura, J Turkson, S Zhang, ... Oncogene 21 (13), 2000-2008, 2002 | 1631 | 2002 |
| Src kinases as therapeutic targets for cancer LC Kim, L Song, EB Haura Nature reviews Clinical oncology 6 (10), 587-595, 2009 | 840 | 2009 |
| DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer Z Zheng, T Chen, X Li, E Haura, A Sharma, G Bepler New England Journal of Medicine 356 (8), 800-808, 2007 | 691 | 2007 |
| Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes JD McKay, RJ Hung, Y Han, X Zong, R Carreras-Torres, DC Christiani, ... Nature genetics 49 (7), 1126-1132, 2017 | 634 | 2017 |
| Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer EB Haura, J Turkson, R Jove Nature clinical practice Oncology 2 (6), 315-324, 2005 | 627 | 2005 |
| Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation J Turkson, D Ryan, JS Kim, YI Zhang, Z Chen, E Haura, A Laudano, ... Journal of Biological Chemistry 276 (48), 45443-45455, 2001 | 615 | 2001 |
| Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer PS Hammerman, ML Sos, AH Ramos, C Xu, A Dutt, W Zhou, LE Brace, ... Cancer discovery 1 (1), 78-89, 2011 | 598 | 2011 |
| Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study K Park, EB Haura, NB Leighl, P Mitchell, CA Shu, N Girard, S Viteri, ... Journal of Clinical Oncology 39 (30), 3391-3402, 2021 | 572 | 2021 |
| Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells L Song, J Turkson, JG Karras, R Jove, EB Haura Oncogene 22 (27), 4150-4165, 2003 | 489 | 2003 |
| Stat3 regulates genes common to both wound healing and cancer DJ Dauer, B Ferraro, L Song, B Yu, L Mora, R Buettner, S Enkemann, ... Oncogene 24 (21), 3397-3408, 2005 | 470 | 2005 |
| Nicotine induces cell proliferation, invasion and epithelial‐mesenchymal transition in a variety of human cancer cell lines P Dasgupta, W Rizwani, S Pillai, R Kinkade, M Kovacs, S Rastogi, ... International Journal of Cancer 124 (1), 36-45, 2009 | 441 | 2009 |
| Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). MG Kris, BE Johnson, DJ Kwiatkowski, AJ Iafrate, II Wistuba, SL Aronson, ... Journal of Clinical Oncology 29 (18_suppl), CRA7506-CRA7506, 2011 | 398 | 2011 |
| Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin P Dasgupta, R Kinkade, B Joshi, C DeCook, E Haura, S Chellappan Proceedings of the National Academy of Sciences 103 (16), 6332-6337, 2006 | 391 | 2006 |
| Nicotine induces cell proliferation by β-arrestin–mediated activation of Src and Rb–Raf-1 pathways P Dasgupta, S Rastogi, S Pillai, D Ordonez-Ercan, M Morris, E Haura, ... The Journal of clinical investigation 116 (8), 2208-2217, 2006 | 378 | 2006 |
| Oral iron supplementation after blood donation: a randomized clinical trial JE Kiss, D Brambilla, SA Glynn, AE Mast, BR Spencer, M Stone, ... Jama 313 (6), 575-583, 2015 | 354* | 2015 |
| Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity J Turkson, JS Kim, S Zhang, J Yuan, M Huang, M Glenn, E Haura, S Sebti, ... Molecular cancer therapeutics 3 (3), 261-269, 2004 | 339 | 2004 |
| Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial BC Creelan, C Wang, JK Teer, EM Toloza, J Yao, S Kim, AM Landin, ... Nature medicine 27 (8), 1410-1418, 2021 | 336 | 2021 |
| HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma H Zheng, W Zhao, C Yan, CC Watson, M Massengill, M Xie, C Massengill, ... Clinical Cancer Research 22 (16), 4119-4132, 2016 | 329 | 2016 |